

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
11 August 2005 (11.08.2005)

PCT

(10) International Publication Number
WO 2005/072045 A2

(51) International Patent Classification: Not classified

(CA). PASTRAK, Aleksandra [CA/CA]; 120 Glenvale Boulevard, Toronto, Ontario M4G 2V9 (CA). HEW, Yin [SG/SG]; c/o Transition Therapeutics Inc., 415 Yonge Street, Suite 1003, Toronto, Ontario, Canada M5B 2E7 (SG).

(21) International Application Number: PCT/CA2005/000099

(74) Agents: KURDYDYK, Linda et al.; McCarthy Tetrault, Suite 4700, P.O. Box 48, 66 Wellington Street West, Toronto Dominion Bank Tower (CA).

(22) International Filing Date: 28 January 2005 (28.01.2005)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

(26) Publication Language: English

(30) Priority Data:

60/540,803 30 January 2004 (30.01.2004) US
60/540,804 30 January 2004 (30.01.2004) US

(71) Applicant (for all designated States except US):


WARATAH PHARMACEUTICALS, INC. [CA/CA]; 415 Yonge Street, Suite 1103, Toronto, Ontario M5B 2E7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CRUZ, Antonio [CA/CA]; 89 Dunloc Road, Toronto, Ontario M5P 2T7

[Continued on next page]

(54) Title: COMBINED USE OF A GLP-1 AGONIST AND GASTRIN COMPOUNDS



† No survivors in the control group

WO 2005/072045 A2

(57) Abstract: The invention relates to compositions, conjugates, and methods for the prevention and/or treatment of a condition and/or disease comprising a therapeutically effective amount of a GLP-1 agonist and a gastrin compound. The combination of a GLP-1 agonist and a gastrin compound provides beneficial effects, in particular sustained beneficial effects, in the prevention and/or treatment of conditions and/or diseases for which either a GLP-1 agonist or a gastrin compound have been demonstrated to have a therapeutic effect, including but not limited to diabetes, hypertension, chronic heart failure, fluid retentive states, obesity, metabolic syndrome and related diseases and disorders. Combinations of a GLP-1 agonist and a gastrin compound can be selected to provide unexpectedly additive effects or synergistic effects.

BEST AVAILABLE COPY



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*